semaglutide adverse effects This figure depicts the common and severe associated What are the long-term side

Heres the realistic timeline: Phase 3 trials (AMAZE program): - AMAZE 1 (obesity) started February 2026, enrolling ~1,150 participants - Primary completion estimated: June 2029 - Phase 3 in T2D also being planned following the ADA 2026 data US FDA approval (projected): Q4 2030 at the earliest (GlobalData estimate) EU EMA approval (projected): Q1 2031 at the earliest Bulgaria and Eastern Europe: Typically 612 months after EMA approval for market access, depending on national reimbursement negotiations

We're moving beyond "weight loss drugs" toward thorough metabolic therapies that address the root causes of multiple chronic conditions simultaneously

97 In addition to CB receptors, it has been suggested that CBD is also associated with other pharmacological substrates

Sawyer SM, Whitelaw M, LeGrange D, Yeo M, Hughes D